NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Can-Fite Secures Brazilian Patent for Sexual Dysfunction Treatment

Can-Fite BioPharma receives Brazilian patent protection for its A3 adenosine receptor agonist drug targeting sexual dysfunction, expanding its presence in Latin America's pharmaceutical market.

Can-Fite Secures Brazilian Patent for Sexual Dysfunction Treatment
"Cryo-EM structures of adenosine receptor A3AR", Credit: Nature
Already have an account? Sign in.
12/26/2025 · 8:27 AM
CANF
/ Don’t stop at just one post.

Related↓

Can-Fite’s Namodenoson Shows Strong Safety Profile in Advanced Pancreatic Cancer Patients
03/04/2026 · 8:15 AM

Can-Fite’s Namodenoson Shows Strong Safety Profile in Advanced Pancreatic Cancer Patients

Can-Fite BioPharma shares positive Phase 2a results for Namodenoson in treating advanced pancreatic cancer, highlighting its safety and potential for better survival outcomes in tough cases.

/ Subscriber only
/ Read more

Feed↓

Qualcomm Nears $4 Billion Acquisition of AI Startup Modular
Featured/ 06/22/2026 · 5:38 PM

Qualcomm Nears $4 Billion Acquisition of AI Startup Modular

The deal would boost Qualcomm’s AI software capabilities and challenge NVIDIA’s dominance in AI inference.

/ Subscriber only
Avis Budget Group Settles $650 Million Lawsuit with Pentwater
Featured/ 06/22/2026 · 5:22 PM

Avis Budget Group Settles $650 Million Lawsuit with Pentwater

Avis Budget Group has reached a $650 million settlement with Pentwater Capital to resolve its short-swing profits lawsuit. The agreement is subject to court approval.

/ Subscriber only
Lucid Cuts 18% of U.S. Workforce and Eliminates COO Role to Cut Costs
06/22/2026 · 3:46 PM

Lucid Cuts 18% of U.S. Workforce and Eliminates COO Role to Cut Costs

The restructuring is expected to deliver $158 million in annual cost savings.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe